Voyager is committed to maintaining a strong balance sheet that supports the advancement and growth of its platform and pipeline. Based on Voyager’s current operating plans, the company expects its cash, cash equivalents, and marketable securities, along with anticipated collaboration reimbursements and interest income, to be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2028. The Company has the potential to earn additional non-dilutive capital that is not assumed in the cash runway guidance of up to $2.4 billion in development milestone payments including up to $35 million from GBA and FA programs entering the clinic.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYGR:
- Voyager Therapeutics, Transition Bio entered into drug discovery collab
- Voyager Therapeutics Advances Alzheimer’s Study with VY7523
- Voyager Therapeutics: Strategic Positioning and Regulatory Endorsements Drive Buy Rating
- Voyager Therapeutics: Promising Alzheimer’s Portfolio and Innovative NeuroShuttle Platform Justify Buy Rating